CYP19A1 and breast cancer: The primary endpoint was met, with a median PFS of 23.8 months vs 13.0 months in the ribociclib vs placebo group (HR = 0.553; 95% CI 0.441–0.694; P = 9.83 × 10−8) (Tripathy D et al. First-line ribociclib or placebo combined with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the randomized Phase III MONALEESA-7 trial.